Table 2.

Univariate and multivariate analyses of prognostic factors on overall Survival

Factor	N	Survival rate (%)		Univariate analysis (P value)	multivariate analysis (P value)	Hazard ratio	95% CI
		1-year	3-year
HBV infection				0.003	0.463	0.908	0.702-1.175
Yes	187	59.9	35.8
No	183	51.4	21.3
Hepatolithiasis				< 0.001	0.173	1.328	0.883-1.998
Yes	36	38.9	8.3
No	334	57.5	30.8
AST				0.017	0.588	1.088	0.802-1.476
≤ 37 U/L	260	58.5	31.9
> 37 U/L	110	49.1	20.9
PA				< 0.001	0.015	1.447	1.076-1.947
< 170 mg/L	71	40.8	11.3
≥ 170 mg/L	299	59.2	32.8
r-GT				< 0.001	0.557	1.094	0.810-1.477
≤ 61 U/L	156	67.3	41.0
> 61 U/L	214	47.2	19.6
ALP				< 0.001	0.349	1.149	0.859-1.538
≤ 129 U/L	241	64.7	36.1
> 129 U/L	129	38.8	14.7
CA19-9				< 0.001	0.009	1.438	1.096-1.886
≤ 39 U/mL	170	71.2	42.4
> 39 U/mL	200	42.5	17.0
CEA				< 0.001	0.002	1.732	1.224-2.451
≤ 10 µg/L	315	60.3	33.0
> 10 µg/L	55	29.1	3.6
Tumor number				< 0.001	< 0.001	1.781	1.381-2.298
single	233	66.5	36.9
multiple	137	37.2	14.6
Tumor size				< 0.001	0.557	1.091	0.817-1.456
< 5 cm	130	70.0	42.3
≥ 5 cm	240	47.9	21.3
Capsule formation				0.012	0.210	0.732	0.450-1.192
Yes	32	75.0	46.9
No	338	53.8	26.9
Vascular invasion				< 0.001	< 0.001	1.784	1.370-2.323
Yes	112	41.1	13.4
No	258	62.0	35.3
Regional lymphatic metastasis				< 0.001	< 0.001	2.003	1.490-2.693
Yes	70	27.1	5.7
No	300	62.3	34.0
Local extrahepatic metastasis				< 0.001	0.008	1.506	1.112-2.039
Yes	67	28.4	6.0
No	303	61.7	33.7

ICC: intrahepatic cholangiocarcinoma; HBV: hepatitis B virus; alanine transaminase (ALT); aspartate transaminase (AST); PA: pre-albumin; ALP: alkaline phosphatase; r-GT: r-glutamyltransferase; CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen.